Strategic Global Advisors’s AstraZeneca AZN Stock Holding History

Strategic Global Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$809K	Sell	4,104 -949	-19%	-$183K	0.13%	122
2025 Q4	$929K	Buy	5,053 +3,398	+205%	+$596K	0.14%	114
2025 Q3	$254K	Buy	1,655 +41	+3%	+$6.21K	0.04%	131
2025 Q2	$226K	Buy	1,614 +156	+11%	+$21.9K	0.04%	138
2025 Q1	$214K	Sell	1,458 -3,164	-68%	-$458K	0.04%	137
2024 Q4	$606K	Sell	4,622 -424	-8%	-$59.4K	0.11%	112
2024 Q3	$786K	Buy	5,046 +2,569	+104%	+$415K	0.15%	110
2024 Q2	$723K	Sell	2,477 -2,272	-48%	-$342K	0.15%	108
2024 Q1	$643K	Buy	+4,749	New	+$629K	0.14%	111
2021 Q4	–	Sell	-13,538	Closed	-$1.63M	–	140
2021 Q3	$1.63M	Buy	+13,538	New	+$1.58M	0.24%	110

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Strategic Global Advisors's AZN Position: Q1 2026 in Review

Strategic Global Advisors reduced its AstraZeneca (AZN) stake by 19% in Q1 2026, selling an estimated $183K and leaving 4,104 shares worth $809K. The position accounts for 0.13% of the portfolio, ranked #122.

Strategic Global Advisors first reported a position in AZN in Q3 2021 and has held it in 10 quarters since. The position peaked at $1.63M in Q3 2021. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Strategic Global Advisors held 4,104 shares of AstraZeneca worth $809K as of Q1 2026.
Strategic Global Advisors sold 949 AstraZeneca shares in Q1 2026, an estimated $183K.
AstraZeneca made up 0.13% of Strategic Global Advisors's portfolio in Q1 2026, its #122 holding.
Strategic Global Advisors first reported a position in AstraZeneca in Q3 2021 and has held it in 10 quarters since.
Strategic Global Advisors's AstraZeneca position peaked at $1.63M in Q3 2021.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Strategic Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.